NCT01154166 - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa | Biotech Hunter

Enrollment

347

Participants

Timeline

Start Date

February 15, 2010

Primary Completion Date

September 1, 2011

Study Completion Date

September 29, 2011

Conditions

Parkinson Disease

Interventions

DRUG

ReQuip PR

If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.

DRUG

Placebo

Trial Locations (18)